- Home
- ROIV
as 09-05-2025 4:00pm EST
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 8.6B | IPO Year: | N/A |
| Target Price: | $15.50 | AVG Volume (30 days): | 5.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.73 - $13.08 | Next Earning Date: | 08-11-2025 |
| Revenue: | $23,233,000 | Revenue Growth: | -35.86% |
| Revenue Growth (this year): | -11.38% | Revenue Growth (next year): | 281.14% |
Stock Insider Trading Activity of Roivant Sciences Ltd. (ROIV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ramaswamy Vivek | ROIV | 10% Owner | Sep 5 '25 | Sell | $12.96 | 385,816 | $5,000,175.36 | 35,508,359 | |
| Ramaswamy Vivek | ROIV | 10% Owner | Sep 4 '25 | Sell | $12.92 | 194,933 | $2,518,534.36 | 35,508,359 | |
| Ramaswamy Vivek | ROIV | 10% Owner | Sep 3 '25 | Sell | $12.50 | 1,195,000 | $14,937,500.00 | 35,508,359 | |
| Venker Eric | ROIV | President & Immunovant CEO | Aug 20 '25 | Sell | $11.72 | 100,000 | $1,172,000.00 | 1,653,585 | |
| Venker Eric | ROIV | President & COO | Jun 20 '25 | Sell | $11.45 | 100,000 | $1,145,000.00 | 1,653,585 | |
| Ramaswamy Vivek | ROIV | 10% Owner | Jun 18 '25 | Sell | $11.46 | 1,142,273 | $13,084,795.92 | 35,508,359 |
Latest Roivant Sciences Ltd. News
ROIV Breaking Stock News: Dive into ROIV Ticker-Specific Updates for Smart Investing
MT Newswires
2 months ago
Roivant Sciences Insider Sold Shares Worth $1,145,000, According to a Recent SEC Filing
Insider Monkey
2 months ago
Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 06/24/2025
GlobeNewswire
3 months ago
Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics
GlobeNewswire
3 months ago
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
Argus Research
3 months ago
Daily – Vickers Top Buyers & Sellers for 06/09/2025
GlobeNewswire
3 months ago
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update
GuruFocus.com
3 months ago
What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings
Compare ROIV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ROIV Roivant Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.